Mirjam G Wild, Felix Kreidel, Michaela M Hell, Fabien Praz, Markus Mach, Matti Adam, David Reineke, Hendrik Ruge, Sebastian Ludwig, Lenard Conradi, Tanja K Rudolph, Sabine Bleiziffer, Jörg Kellermair, Andreas Zierer, Georg Nickenig, Marcel Weber, Anna Sonia Petronio, Cristina Giannini, Gry Dahle, Kjell A Rein, Augustin Coisne, André Vincentelli, Christophe Dubois, Alison Duncan, Cesare Quarto, Axel Unbehaun, Ignacio Amat-Santos, Javier Cobiella, Nicolas Dumonteil, Rodrigo Estevez-Loureiro, Andrea Fumero, Tobias Geisler, Philipp Lurz, Antonio Mangieri, Vanessa Monivas, Thilo Noack, Luis Nombela Franco, Miguel A Pinon, Lukas Stolz, Didier Tchétché, Thomas Walter, Bernhard Unsöld, Stephan Baldus, Martin Andreas, Jörg Hausleiter, Ralph S von Bardeleben
AIMS: Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real-world data have not yet been reported. This study aimed to assess procedural and 30-day outcomes of TMVI in a real-world patient cohort. METHOD AND RESULTS: All consecutive patients undergoing implantation of a transapically delivered self-expanding valve at 26 European centres from January 2020 to April 2021 were included in this retrospective observational registry...
January 22, 2022: European Journal of Heart Failure